- Home
- CHY vs PRTA Comparison
CHY vs PRTA Comparison
Compare CHY & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHY | PRTA |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.3M | 595.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CHY | PRTA |
|---|---|---|
| Price | $11.38 | $10.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $18.86 |
| AVG Volume (30 Days) | 128.3K | ★ 584.1K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 10.11% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $11,786,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $819.08 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.97 | $4.32 |
| 52 Week High | $12.16 | $17.66 |
Technical Indicators
Market Signals| Indicator | CHY | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 46.59 | 49.53 |
| Support Level | $11.54 | $9.69 |
| Resistance Level | $11.62 | $10.50 |
| Average True Range (ATR) | 0.13 | 0.56 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 59.13 | 36.44 |
Price Performance
Historical ComparisonAbout CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.